Stock of the Day

September 16, 2022

Medpace (MEDP)

$618.47
-$10.13 (-1.6%)
Market Cap: $17.26B

About Medpace

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

Today's Trend

Medpace Holdings, Inc. (NASDAQ: MEDP) shares are under pressure as investors weigh substantial insider selling against a favorable analyst revision and continued operating growth.

  • UBS upgraded Medpace from “sell” to “hold” and raised its price target to $673 from $405. The new target is above recent trading levels, suggesting UBS sees reduced downside risk. UBS upgrades Medpace and raises price target
  • Medpace’s latest quarterly results remain supportive of its growth story: revenue rose 17.2% year over year to $707.3 million, while earnings of $4.25 per share exceeded the $3.98 consensus estimate. Fiscal 2026 earnings guidance also remains intact.
  • Analyst sentiment is broadly mixed, with most firms maintaining “hold” ratings. The consensus price target is approximately $602.27, close to recent levels, indicating that much of the company’s growth may already be reflected in its valuation.
  • CEO August Troendle sold 21,966 shares for approximately $13.7 million on September 30, after selling 26,701 shares worth about $16.6 million on September 29. The combined sales totaled roughly $30.3 million and materially reduced his direct ownership. Additional smaller sales were also reported, raising concerns about insider confidence and contributing to the stock’s weakness. Troendle nevertheless retains a substantial stake. Medpace CEO stock sale SEC filing
← Previous Stock of the DayNext Stock of the Day →

Recent News